Group 1 - The company, Brainstorm Cell Therapeutics Inc. (06681.HK), has recently entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote product marketing and market expansion in Singapore [1] - The collaboration aims to jointly advance the development of the digital health industry [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources for targeted recommendations and full-service support [2]. - Market expansion efforts will involve integrating resources such as products, channels, brands, and technology to penetrate Singapore's healthcare system, focusing on private and public hospitals [2]. Group 2: Long-term Development Opportunities - This partnership is expected to enhance the company's international presence and expand into Southeast Asia, building on previous experiences in Hong Kong and Macau [3]. - The collaboration aims to strengthen the company's brand authority in digital healthcare and expedite product integration into local medical institutions, thereby broadening its market reach [3].

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote and expand its digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation Details - The cooperation includes product promotion, where the company will localize its cognitive disorder digital therapy products for Singapore, while Natural Health Solutions will leverage its offline stores and member resources to recommend the products to target users and provide full-service support [2]. - Market expansion collaboration will involve integrating resources such as products, channels, brands, and technology to jointly develop the Singapore market, focusing on introducing the company's products into leading private and public hospitals [2]. Group 2: Long-term Development Opportunities - The cooperation is expected to deepen the company's international presence and expand into overseas markets, marking the official launch of its Southeast Asia market strategy, building on prior experiences in Hong Kong and Macau [3]. - This partnership is anticipated to enhance the company's brand influence and commercial network in the digital healthcare sector, facilitating quicker product integration into local medical institutions and diversifying into various digital health management markets [3].

Core Viewpoint - The company has entered into a strategic cooperation agreement with Natural Health Solutions Programme Group Holdings to promote digital health products in the Singapore market, addressing the challenges of an aging population and increasing rates of cognitive disorders [1][2]. Group 1: Strategic Cooperation - The agreement focuses on product promotion and market expansion in Singapore, leveraging the local government's initiatives for early screening and health management for cognitive disorders [1]. - The company will localize its cognitive disorder digital therapy products for the Singapore market, while Natural Health Solutions will utilize its network to recommend these products to target users [2]. Group 2: Market Expansion - The collaboration aims to integrate resources such as products, channels, and technology to penetrate the Singapore healthcare system, particularly targeting private and public hospitals [2]. - This partnership marks the company's formal entry into the Southeast Asian market, building on its previous experiences in Hong Kong and Macau [3]. Group 3: Long-term Opportunities - The cooperation is expected to enhance the company's international presence and brand influence, allowing it to export its digital therapy expertise to other supportive regions [3]. - The partnership will strengthen the company's authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 訂立戰略合作協議以拓展新加坡市場及推動國際化佈局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者瞭解本集團最新業務發展情況。 根據協議，雙方合作主要包括以下內容：(I)產品推廣合作：本公司負責認知障礙 數字療法產品在新加坡的本土化適配、系統落地及人員培訓支持；萊賀思寶將依 託其全部線下門店及會員資源，向目標用戶定向推薦本公司產品，並負責全流程 服務，包括產品介紹、試用引導、購買轉化及售後支持。(II)市場拓展協同：雙方 整合產品、渠道、品牌與技術等資源，共同開拓新加坡市場，重點推動本公司產 品進入新加坡頭部私立醫院及公立醫院體系，提升產品在當地醫療系統中的應用 與普及。 ...

Core Viewpoint - The brain-machine interface sector is experiencing a surge in stock prices following the release of a new regulatory framework by the National Medical Products Administration (NMPA) in China, which includes a list of prioritized high-end medical devices for approval [1] Group 1: Stock Performance - Heartway Medical-B (06609) saw a price increase of 12.22%, reaching 54 HKD [1] - Brain Dynamics-B (06681) rose by 7.78%, trading at 6.79 HKD [1] - Nanjing Panda Electronics (00553) increased by 7.14%, with a price of 4.65 HKD [1] Group 2: Regulatory Developments - On December 26, the NMPA published the "Priority Approval List for High-End Medical Devices (2025 Edition)," which includes eight products, such as implantable brain-machine interface devices [1] - The list outlines the technical parameters and expected uses of the products [1] - The NMPA is actively promoting faster and better market entry for brain-machine interface devices through a dedicated working meeting [1] Group 3: Market Outlook - Guotai Junan Securities notes that recent policies have shown strong support for innovation in medical devices [1] - The brain-machine interface sector has diverse application scenarios and rich product and research pathways, indicating significant future potential [1] - With the support of product registration and medical insurance policy initiatives, commercialization is expected to accelerate [1]

| 代码 | 名称 | | 涨跌幅 √ | 最新价 | 总市值 | 年初至今涨跌 | | --- | --- | --- | --- | --- | --- | --- | | 06609 | 心玮医疗-B | 0 | 12.22% | 54.000 | 20.69亿 | 146.01% | | 06681 | 脑动极光-B | | 7.78% | 6.790 | 85.98亿 | 110.87% | | 00553 | 南京熊猫电子股份 | | 7.14% | 4.650 | 42.49亿 | 35.57% | | 02203 | 脑洞科技 | | 5.50% | 0.230 | 1.84亿 | 1.77% | | 02172 | 微创脑科学 | | 3.29% | 11.000 | 63.36亿 | 30.18% | 港股市场脑机接口板块集体大涨，其中，心玮医疗-B涨超12%，脑动极光-B、南京熊猫电子股份涨超 7%，脑洞科技涨超5%，微创脑科学涨超3%。消息面上，12月28日，第五届脑科学前沿与产业大会暨 2025深圳脑机接口博览会启幕，"粤港澳大湾区脑科学与中枢神经疾病AI创新联盟"正式启动。 ...

（文章来源：每日经济新闻） 每经AI快讯，脑动极光-B(06681.HK)涨超3%，截至发稿，涨3.33%，报6.51港元，成交额4833.44万港 元。 ...

Core Viewpoint - The company, Brain Dynamics Aurora-B (06681), has seen its stock price increase by over 5%, currently trading at 6.51 HKD with a transaction volume of 48.33 million HKD, following the announcement of its participation in a significant national technology project focused on the prevention and treatment of cognitive disorders related to intracranial atherosclerotic stenosis [1] Group 1: Project Involvement - The company’s wholly-owned subsidiary, Smart Genius Technology, is a key collaborator in the national major science and technology project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The project specifically addresses the challenges in diagnosing cognitive disorders caused by intracranial atherosclerotic stenosis (ICAS) and aims to establish a deep reasoning model and a comprehensive management system for early disease screening, risk assessment, and intervention tools [1] Group 2: Technological Development - As a core technology unit, the company will be responsible for the development of the deep reasoning model related to cognitive disorders caused by ICAS and the construction of a digital diagnosis and treatment platform [1] - The project has recently been officially launched, indicating a significant step forward in the company's technological capabilities and contributions to the healthcare sector [1] Group 3: Collaboration and Recognition - Smart Genius Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has successfully applied for the establishment of the "Beijing Key Laboratory of Digital Medical for Cognitive Disorders," which has also been officially approved [1] - This collaboration highlights the company's commitment to advancing research and development in the field of cognitive health and its strategic partnerships with leading medical institutions [1]

Core Viewpoint - Brain动极光-B (06681) has seen a stock price increase of over 5%, currently trading at 6.51 HKD with a transaction volume of 48.33 million HKD, following the announcement of its participation in a significant national technology project focused on the treatment of cognitive disorders related to intracranial atherosclerotic stenosis [1] Group 1: Company Developments - Brain动极光's wholly-owned subsidiary, 智精灵科技, is a key collaborator in the national technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases," specifically focusing on cognitive disorders related to intracranial atherosclerotic stenosis [1] - The project aims to establish key technologies for digital diagnosis and treatment of cognitive disorders, utilizing deep reasoning large models and a comprehensive management system for early disease screening, risk assessment, and intervention tools [1] - 智精灵科技 has also recently received approval for the establishment of the "Beijing Key Laboratory for Digital Medical Treatment of Cognitive Disorders," in collaboration with Capital Medical University Xuanwu Hospital [1] Group 2: Industry Context - The national technology major project addresses the clinical challenges of diagnosing and treating cognitive disorders caused by intracranial atherosclerotic stenosis (ICAS), indicating a growing focus on advanced digital health solutions in the medical field [1] - As a core technology provider, Brain动极光 is tasked with the development of deep reasoning models related to cognitive disorders and the construction of a digital diagnosis and treatment platform, highlighting the company's strategic positioning in the healthcare technology sector [1]